chr4-119186094-G-A
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BS2
The NM_016599.5(MYOZ2):c.689G>A(p.Arg230Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000403 in 1,613,628 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R230W) has been classified as Likely benign.
Frequency
Consequence
NM_016599.5 missense
Scores
Clinical Significance
Conservation
Publications
- hypertrophic cardiomyopathy 16Inheritance: AD Classification: LIMITED Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Ambry Genetics
- hypertrophic cardiomyopathyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -4 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_016599.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MYOZ2 | NM_016599.5 | MANE Select | c.689G>A | p.Arg230Gln | missense | Exon 6 of 6 | NP_057683.1 | ||
| MYOZ2 | NM_001440645.1 | c.*102G>A | 3_prime_UTR | Exon 7 of 7 | NP_001427574.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MYOZ2 | ENST00000307128.6 | TSL:1 MANE Select | c.689G>A | p.Arg230Gln | missense | Exon 6 of 6 | ENSP00000306997.6 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151922Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000239 AC: 6AN: 251354 AF XY: 0.0000442 show subpopulations
GnomAD4 exome AF: 0.0000424 AC: 62AN: 1461706Hom.: 1 Cov.: 31 AF XY: 0.0000413 AC XY: 30AN XY: 727168 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151922Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74200 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not specified Uncertain:1
The Arg230Gln variant in MYOZ2 has not been reported in individuals with cardiom yopathy or in large population studies. Computational analyses (biochemical amin o acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. Additional studies are n eeded to fully assess the clinical significance of this variant.
Hypertrophic cardiomyopathy Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 230 of the MYOZ2 protein (p.Arg230Gln). This variant is present in population databases (rs727503332, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with MYOZ2-related conditions. ClinVar contains an entry for this variant (Variation ID: 164730). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt MYOZ2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Cardiovascular phenotype Uncertain:1
The p.R230Q variant (also known as c.689G>A), located in coding exon 5 of the MYOZ2 gene, results from a G to A substitution at nucleotide position 689. The arginine at codon 230 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at